Dynavax Technologies has been granted a patent for compounds that act as antagonists of toll-like receptors, inhibiting immune response. The compounds, including those of formula (I), are effective in treating autoimmune diseases affecting various organs and systems. GlobalData’s report on Dynavax Technologies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Dynavax Technologies, Personalized cancer vaccines was a key innovation area identified from patents. Dynavax Technologies's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of autoimmune diseases using toll-like receptor antagonists
A recently granted patent (Publication Number: US11827641B2) discloses a method for treating or ameliorating autoimmune diseases or disorders affecting various organs and systems in the body. The method involves administering a therapeutically effective amount of a specific compound or its pharmaceutically acceptable salt or solvate to individuals in need of treatment. The compound, represented by formula (I), targets autoimmune conditions affecting the skin, heart, liver, endocrine glands, digestive system, blood, connective tissue, muscle, nervous system, eye, or inner ear.
The patent outlines specific criteria for the compound's chemical structure and its administration, including the route of delivery such as oral, mucosal, intramuscular, subcutaneous, intravenous, topical, or transdermal. Additionally, the method allows for the co-administration of other therapeutic agents like nonsteroidal anti-inflammatory drugs, corticosteroids, antimalarial drugs, immunosuppressive drugs, or biologics to enhance the treatment of autoimmune diseases. The autoimmune conditions targeted by this method range from alopecia areata, psoriasis, and systemic scleroderma in the skin to autoimmune myocarditis in the heart, autoimmune hepatitis in the liver, and various disorders affecting the endocrine glands, digestive system, blood, connective tissue, muscle, nervous system, eye, and inner ear. This patent provides a comprehensive approach to addressing a wide array of autoimmune diseases and disorders through a specific compound and its administration protocol.
To know more about GlobalData’s detailed insights on Dynavax Technologies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
